Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Success Stories: EvoLV's Impact on Life Sciences Companies in Eastvale

Feb 13, 2026

Revolutionizing Life Sciences in Eastvale

The life sciences sector in Eastvale has witnessed transformative growth, thanks to the innovative solutions provided by EvoLV. This dynamic company has been at the forefront of integrating cutting-edge technology with scientific research, paving the way for groundbreaking advancements. Their impact on numerous life sciences companies in the region has been nothing short of extraordinary.

Eastvale, known for its vibrant community of research-driven organizations, has greatly benefited from EvoLV’s expertise. By fostering a collaborative environment, EvoLV has enabled local companies to streamline their operations, enhance research capabilities, and ultimately, deliver better results.

life sciences innovation

Driving Innovation Through Technology

One of the key contributions of EvoLV is its ability to integrate technology into the core operations of life sciences companies. By providing advanced data analytics and automation tools, EvoLV has empowered these organizations to make informed decisions with greater efficiency. This has not only improved productivity but also accelerated the pace of scientific discovery.

Moreover, EvoLV's solutions have helped companies manage complex data sets with ease. By implementing robust data management systems, they have ensured that researchers can access and analyze information more effectively. This has led to more accurate results and a deeper understanding of various scientific phenomena.

technology in science

Enhanced Collaboration and Networking

EvoLV has also played a pivotal role in fostering collaboration among life sciences companies in Eastvale. By organizing workshops, seminars, and networking events, EvoLV has created platforms for knowledge exchange and partnership. These initiatives have enabled companies to share insights, collaborate on projects, and leverage each other's strengths.

Additionally, EvoLV’s partnerships with academic institutions have further enriched the research ecosystem in Eastvale. By bridging the gap between academia and industry, they have facilitated the transfer of knowledge and expertise, driving innovation and growth in the region.

collaboration network

Success Stories and Testimonials

The impact of EvoLV on life sciences companies in Eastvale is best illustrated through success stories and testimonials from satisfied partners. Several companies have reported significant improvements in their research outcomes and operational efficiency after implementing EvoLV's solutions.

  • A leading biotech firm achieved a 30% increase in research productivity.
  • Another company successfully reduced its data processing time by half, allowing for faster project completion.
  • Testimonials highlight how EvoLV's support has led to more innovative product development.

Future Prospects and Expansion

Looking ahead, EvoLV is poised to continue its transformative journey in the life sciences sector. With plans to expand its services and reach, the company aims to support even more organizations in their quest for scientific excellence. Their commitment to innovation and collaboration promises to drive further advancements in Eastvale and beyond.

As more companies recognize the value of EvoLV’s solutions, the future looks bright for life sciences in Eastvale. The region is set to remain a hub of scientific innovation, with EvoLV leading the charge towards a more efficient and effective research landscape.

future innovation